A Clinical Trial to Evaluate the Efficacy and Safety of Pitavastatin/Fenofibrate in Complex-dyslipidemia

Inclusion Criteria: * High risk patient to Coronary Heart Disease * At visit 1(Screening) 1. If treated with Pitavastatin 2mg monotherapy 4 weeks prior to this study : LDL-C\<100mg/dL and 150mg/dL≤TG\<500mg/dL, randomize without run-in period 2. If non treated with Pitavastatin 2mg monotherapy 4 weeks prior to this study : LDL-C≥100mg/dL and 150mg/dL≤TG\<500mg/dL, treatment of Pitavastatin 2mg for 4 weeks(run-in period) * LDL-C\<100mg/dL and 150mg/dL≤TG\<500mg/dL after 4 weeks of Pitavastatin 2mg monotherapy Exclusion Criteria: * Subject with acute artery disease * Subject with congestive heart failure(NYHA class III\~IV) or uncontrolled arrhythmia * Secondary or iatrogenic dyslipidemia caused by hypothyroidism, nephrotic syndrome etc. * AST or ALT \> 2XULN, Serum Creatinine \> 2.5mg/dL, Creatinine phosphokinase \> 2XULN * Subject with gall bladder disease or pancreatitis * Uncontrolled hypertension * Endocrine or metabolic disease affected on serum lipid or liprotein * Subject with medical history of myopathy or rhabdomyolysis caused by Statin treatment, hereditary myopathy or family history * Not eligible to participate for the study at the discretion of investigator